Protective antibody responses against A(H1N1)pdm09 primed by infection and recalled by intranasal vaccination |
| |
| Affiliation: | 1. Department of Pathology, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama 208-0011, Tokyo, Japan;2. Influenza Virus Research Center, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama 208-0011, Tokyo, Japan;1. Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, United States;2. Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, CT, United States;3. University of Rochester Medical Center, Rochester, NY, United States;4. Atlanta Research and Education Foundation, Atlanta, GA, United States;1. State Key Laboratory of Freshwater Ecology and Biotechnology, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China;2. Department of Zoology, College of Life Sciences, Kim Il Song University, Pyongyang, Democratic People''s Republic of Korea;3. University of Chinese Academy of Sciences, Beijing 100049, China;1. College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China;2. School of Pharmaceutical Science, Jiangnan University, Wuxi 214122, China;1. Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry, Ministry of Education, National Engineering Laboratory for Resource Developing of Endangered Chinese Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi’an 710062, Shaanxi, China;2. Department of Chemical Engineering, Queen''s University, Canada |
| |
| Abstract: | ![]()
This study investigated the effects of preceding infection and administration of whole inactivated virus (WIV) vaccine on immune responses against influenza virus challenge. Preceding infection alone provided minimal reduction in virus titer following viral challenge. Single administration of intranasal or subcutaneous WIV vaccine alone failed to reduce virus titers and induce antibody responses. Subcutaneous administration of A/Narita/1/09 (A/NRT)-WIV after A/NRT infection provided complete protection against infection and yielded low nasal IgA and high serum IgG antibody responses. Subcutaneous administration of A/NRT-WIV after A/Puerto Rico/8/34 (A/PR8) infection provided no protection. Conversely, intranasal administration of A/NRT-WIV after A/NRT infection provided complete protection and high nasal IgA and serum IgG antibody responses. While, intranasal administration of A/NRT-WIV after A/PR8 infection provided moderate reduction in viral titer with moderate increases in nasal IgA antibodies. These results indicate that intranasal vaccination is superior to subcutaneous vaccination in inducing protective immune responses after preceding heterologous infection. |
| |
| Keywords: | Intranasal vaccination Influenza Whole inactivated virus vaccine |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
